{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T04:35:08Z","timestamp":1773117308619,"version":"3.50.1"},"reference-count":92,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.pnpbp.2013.07.010","type":"journal-article","created":{"date-parts":[[2013,7,19]],"date-time":"2013-07-19T06:18:04Z","timestamp":1374214684000},"page":"79-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["Neurocognitive endophenotypes in schizophrenia: Modulation by nicotinic receptor systems"],"prefix":"10.1016","volume":"52","author":[{"given":"Kristen M.","family":"Mackowick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mera S.","family":"Barr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria C.","family":"Wing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel A.","family":"Rabin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clairelaine","family":"Ouellet-Plamondon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony P.","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2013.07.010_bb0015","first-page":"639","article-title":"Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia","volume":"17","author":"Adler","year":"1982","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0005","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1176\/ajp.150.12.1856","article-title":"Normalization of auditory physiology by cigarette smoking in schizophrenic patients","volume":"150","author":"Adler","year":"1993","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0010","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/oxfordjournals.schbul.a033320","article-title":"Schizophrenia, sensory gating, and nicotinic receptors","volume":"24","author":"Adler","year":"1998","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0020","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.schres.2007.07.030","article-title":"Early nicotine withdrawal and transdermal nicotine effects on neurocognitive performance in schizophrenia","volume":"100","author":"AhnAllen","year":"2008","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0025","first-page":"395","article-title":"Bupropion: a review of its mechanism of antidepressant activity","volume":"56","author":"Ascher","year":"1995","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb9000","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1038\/sj.npp.1300265","article-title":"Effects of nicotine on leading saccades during smooth pursuit eye movements in smokers and nonsmokers with schizophrenia","volume":"28","author":"Avila","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0045","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/sj.npp.1301423","article-title":"The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls","volume":"33","author":"Barr","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0030","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.schres.2010.05.023","article-title":"Evidence for excessive frontal evoked gamma oscillatory activity in schizophrenia during working memory","volume":"121","author":"Barr","year":"2010","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0035","series-title":"Paper presented at the Canadian College of Neuropsychopharmacology, Toronto, Ontario, Canada","article-title":"Theta\u2013gamma coupling deficits in patients with schizophrenia","author":"Barr","year":"2013"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0040","series-title":"Deficits in theta-gamma coupling in nicotine dependent patients with schizophrenia. Paper presented at the 35th international symposium of the Groupe de Recherche sur le Systeme Nerveux Central (GRSNC). Montreal, Quebec, Canada","author":"Barr","year":"2013"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0050","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijpsycho.2006.07.007","article-title":"Working memory related gamma oscillations in schizophrenia patients","volume":"64","author":"Basar-Eroglu","year":"2007","journal-title":"Int J Psychophysiol"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0055","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s002130100810","article-title":"Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies","volume":"156","author":"Braff","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0065","first-page":"7","article-title":"Effect of smoking history on [3H]nicotine binding in human postmortem brain","volume":"282","author":"Breese","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0060","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0893-133X(00)00121-4","article-title":"Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia","volume":"23","author":"Breese","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0070","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/archpsyc.63.8.907","article-title":"Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors","volume":"63","author":"Brody","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0075","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1176\/appi.ajp.2007.07050724","article-title":"Galantamine for the treatment of cognitive impairments in people with schizophrenia","volume":"165","author":"Buchanan","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0080","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/15504260902869808","article-title":"A nicotine challenge to the self-medication hypothesis in a neurodevelopmental animal model of schizophrenia","volume":"5","author":"Chambers","year":"2009","journal-title":"J Dual Diagn"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0085","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0006-3223(01)01134-9","article-title":"A neurobiological basis for substance abuse comorbidity in schizophrenia","volume":"50","author":"Chambers","year":"2001","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0090","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1021\/jm050069n","article-title":"Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation","volume":"48","author":"Coe","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0095","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0006-3223(00)01101-X","article-title":"Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease","volume":"49","author":"Coyle","year":"2001","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0105","first-page":"001","article-title":"Neurophysiology of nicotine addiction","volume":"20","author":"Dani","year":"2011","journal-title":"J Addict Res Ther"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0110","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.neuroscience.2013.03.029","article-title":"Effects of COMT genotype on sensory gating and its modulation by nicotine: differences in low and high P50 suppressors","volume":"241","author":"de la Salle","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0115","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0893-133X(02)00372-X","article-title":"Nicotine and behavioral markers of risk for schizophrenia: a double-blind, placebo-controlled, cross-over study","volume":"27","author":"Depatie","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0100","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1176\/appi.ajp.2011.11020189","article-title":"Lower \u03b22*-nicotinic acetylcholine receptor availability in smokers with schizophrenia","volume":"169","author":"D'Souza","year":"2012","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0120","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.2967\/jnumed.109.072447","article-title":"Quantification of smoking-induced occupancy of beta2-nicotinic acetylcholine receptors: estimation of nondisplaceable binding","volume":"51","author":"Esterlis","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0125","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.4088\/JCP.v66n0915","article-title":"Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia","volume":"66","author":"Evins","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0135","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/0006-3223(94)00252-X","article-title":"Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia","volume":"38","author":"Freedman","year":"1995","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0130","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1073\/pnas.94.2.587","article-title":"Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus","volume":"94","author":"Freedman","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0140","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/0091-3057(95)02063-2","article-title":"Effects of nicotine withdrawal on central dopaminergic systems","volume":"53","author":"Fung","year":"1996","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0145","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2174\/1568007023339184","article-title":"Regulation of nicotinic acetylcholine receptor numbers and function by chronic nicotine exposure","volume":"1","author":"Gentry","year":"2002","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0150","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1300\/J374v03n03_04","article-title":"Neurobiological links between nicotine addiction and schizophrenia","volume":"3","author":"George","year":"2007","journal-title":"J Dual Diagn"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0155","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.tips.2003.11.003","article-title":"Current pharmacological treatments for nicotine dependence","volume":"25","author":"George","year":"2004","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0170","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0006-8993(98)00537-X","article-title":"Effects of repeated nicotine pre-treatment on mesoprefrontal dopaminergic and behavioral responses to acute footshock stress","volume":"801","author":"George","year":"1998","journal-title":"Brain Res"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0165","first-page":"58","article-title":"Nicotinic modulation of mesoprefrontal dopamine neurons: pharmacologic and neuroanatomic characterization","volume":"295","author":"George","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0175","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0893-133X(01)00296-2","article-title":"Effects of smoking abstinence on visuospatial working memory function in schizophrenia","volume":"26","author":"George","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0160","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.schres.2006.05.022","article-title":"A preliminary study of the effects of cigarette smoking on prepulse inhibition in schizophrenia: involvement of nicotinic receptor mechanisms","volume":"87","author":"George","year":"2006","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0180","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0006-3223(99)00130-4","article-title":"The physiological approach: functional architecture of working memory and disordered cognition in schizophrenia","volume":"46","author":"Goldman-Rakic","year":"1999","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0185","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jama.296.1.47","article-title":"Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial","volume":"296","author":"Gonzales","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0190","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1176\/appi.ajp.160.4.636","article-title":"The endophenotype concept in psychiatry: etymology and strategic intentions","volume":"160","author":"Gottesman","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0195","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.biopsych.2004.06.023","article-title":"Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria","volume":"56","author":"Green","year":"2004","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0200","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/0006-3223(92)90183-Z","article-title":"Startle gating deficits occur across prepulse intensities in schizophrenic patients","volume":"32","author":"Grillon","year":"1992","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0205","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/sj.npp.1300450","article-title":"Effects of nicotine on cognitive deficits in schizophrenia","volume":"29","author":"Harris","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0210","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1037\/0894-4105.12.3.426","article-title":"Neurocognitive deficit in schizophrenia: a quantitative review of the evidence","volume":"12","author":"Heinrichs","year":"1998","journal-title":"Neuropsychology"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0215","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0006-8993(97)01135-9","article-title":"Reduced dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome","volume":"779","author":"Hildebrand","year":"1998","journal-title":"Brain Res"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0220","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/S0893-133X(99)00055-X","article-title":"Behavioral and biochemical manifestations of mecamylamine-precipitated nicotine withdrawal in the rat: role of nicotinic receptors in the ventral tegmental area","volume":"21","author":"Hildebrand","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0225","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/archgenpsychiatry.2011.83","article-title":"Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder","volume":"68","author":"Hong","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0230","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.biopsych.2003.12.023","article-title":"Nicotine effects on brain function and functional connectivity in schizophrenia","volume":"55","author":"Jacobsen","year":"2004","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0235","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1176\/ajp.149.4.488","article-title":"Sensory gating deficits in schizophrenia: new results","volume":"149","author":"Judd","year":"1992","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0240","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1080\/10550490590924728","article-title":"Co-morbidity of smoking in patients with psychiatric and substance use disorders","volume":"14","author":"Kalman","year":"2005","journal-title":"Am J Addict"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0245","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.biopsych.2005.01.003","article-title":"Defining a cognitive function decrement in schizophrenia","volume":"57","author":"Keefe","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0250","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1176\/ajp.142.11.1259","article-title":"The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence","volume":"142","author":"Khantzian","year":"1985","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0255","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/026988119701100205","article-title":"Dopamine, the prefrontal cortex and schizophrenia","volume":"11","author":"Knable","year":"1997","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0260","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.neuroscience.2010.07.012","article-title":"Differential effects of nicotine on P50 amplitude, its gating, and their neural sources in low and high suppressors","volume":"170","author":"Knott","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0265","doi-asserted-by":"crossref","DOI":"10.1177\/0269881113490449","article-title":"Baseline dependency of nicotine's sensory gating actions: similarities and differences in low, medium and high P50 suppressors","author":"Knott","year":"2013","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0270","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1001\/jama.284.20.2606","article-title":"Smoking and mental illness: a population-based prevalence study","volume":"284","author":"Lasser","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0275","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/schbul\/22.3.431","article-title":"Nicotinic receptor function in schizophrenia","volume":"22","author":"Leonard","year":"1996","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0280","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0014-2999(00)00035-2","article-title":"Smoking and schizophrenia: abnormal nicotinic receptor expression","volume":"393","author":"Leonard","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0285","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0893-133X(96)00018-8","article-title":"Nicotine-haloperidol interactions and cognitive performance in schizophrenics","volume":"15","author":"Levin","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0290","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/npp.2012.259","article-title":"A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia","volume":"38","author":"Lieberman","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0295","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/neu.10148","article-title":"Cellular and synaptic mechanisms of nicotine addiction","volume":"53","author":"Mansvelder","year":"2002","journal-title":"J Neurobiol"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0305","first-page":"45","article-title":"Pharmacological evaluation of the antagonism of nicotine's central effects by mecamylamine and pempidine","volume":"254","author":"Martin","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0300","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1016\/0006-2952(89)90106-8","article-title":"What is the nature of mecamylamine's antagonism of the central effects of nicotine?","volume":"38","author":"Martin-Ruiz","year":"1989","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0310","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/mol.106.025130","article-title":"Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors","volume":"70","author":"Mihalak","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0315","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1001\/jama.291.10.1238","article-title":"Actual causes of death in the United States, 2000","volume":"291","author":"Mokdad","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0320","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1521-0391.2013.00313.x","article-title":"Effects of tobacco smoking on neuropsychological function in schizophrenia in comparison to other psychiatric disorders and non-psychiatric controls","volume":"22","author":"Morisano","year":"2013","journal-title":"Am J Addict"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0325","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-25758-2_8","article-title":"Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the a7 nicotinic receptor","author":"Olincy","year":"2012","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0335","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0893-133X(97)00095-X","article-title":"Improvement in smooth pursuit eye movements after cigarette smoking in schizophrenic patients","volume":"18","author":"Olincy","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0330","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0165-1781(03)00022-2","article-title":"Differential effects of cigarette smoking on performance of a smooth pursuit and a saccadic eye movement task in schizophrenia","volume":"117","author":"Olincy","year":"2003","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0340","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/archinte.166.15.1571","article-title":"Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation","volume":"166","author":"Oncken","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0345","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/15504263.2012.663675","article-title":"Varenicline for smoking cessation in schizophrenia: safety and effectiveness in a 12-week, open-label trial","volume":"8","author":"Pachas","year":"2012","journal-title":"J Dual Diagn"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0350","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.psychres.2007.02.009","article-title":"P50 sensory gating ratios in schizophrenics and controls: a review and data analysis","volume":"158","author":"Patterson","year":"2008","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0355","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0165-6147(03)00230-X","article-title":"Nicotine as a modulator of behavior: beyond the inverted U","volume":"24","author":"Picciotto","year":"2003","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0360","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/37120","article-title":"Nicotine activates and desensitizes midbrain dopamine neurons","volume":"390","author":"Pidoplichko","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0365","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/0269881104047273","article-title":"Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders","volume":"18","author":"Sacco","year":"2004","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0380","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/archpsyc.62.6.649","article-title":"Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms","volume":"62","author":"Sacco","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0375","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.schres.2006.03.025","article-title":"Neuropsychological deficits in nonsmokers with schizophrenia: effects of a nicotinic antagonist","volume":"85","author":"Sacco","year":"2006","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0370","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.schres.2008.05.004","article-title":"Effects of galantamine on cognitive deficits in smokers and non-smokers with schizophrenia","volume":"103","author":"Sacco","year":"2008","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0385","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.biopsych.2006.04.006","article-title":"Galantamine improves cognition in schizophrenic patients stabilized on risperidone","volume":"60","author":"Schubert","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0390","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/npp.2011.238","article-title":"Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial","volume":"37","author":"Shim","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0395","first-page":"321","article-title":"Bupropion is a nicotinic antagonist","volume":"295","author":"Slemmer","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0405","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0893-133X(02)00324-X","article-title":"Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia","volume":"27","author":"Smith","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0410","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/sj.npp.1300881","article-title":"Effects of nicotine nasal spray on cognitive function in schizophrenia","volume":"31","author":"Smith","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0400","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.schres.2009.02.001","article-title":"Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder","volume":"110","author":"Smith","year":"2009","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0415","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.drugalcdep.2005.04.002","article-title":"Cigarette smoking topography in smokers with schizophrenia and matched non-psychiatric controls","volume":"80","author":"Tidey","year":"2005","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0420","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/jama.296.1.64","article-title":"Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial","volume":"296","author":"Tonstad","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0425","first-page":"484","article-title":"Nicotine and morphine differentially activate brain dopamine in prefrontocortical and subcortical terminal fields: effects of acute and repeated injections","volume":"261","author":"Vezina","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0430","doi-asserted-by":"crossref","first-page":"654","DOI":"10.4088\/JCP.11m07522","article-title":"A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder","volume":"73","author":"Williams","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0435","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.schres.2010.10.011","article-title":"Spatial working memory impairments induced by cigarette smoking abstinence are correlated with plasma nicotine levels in schizophrenia","volume":"128","author":"Wing","year":"2011","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0440","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.psychres.2011.05.037","article-title":"Neuropsychological performance in patients with schizophrenia and controls as a function of cigarette smoking status","volume":"188","author":"Wing","year":"2011","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0445","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1749-6632.2011.06261.x","article-title":"A review of neurobiological vulnerability factors and treatment implications for comorbid tobacco dependence in schizophrenia","volume":"1248","author":"Wing","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0450","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/YCO.0b013e3283366643","article-title":"Why do patients with schizophrenia smoke?","volume":"23","author":"Winterer","year":"2010","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.07.010_bb0455","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.schres.2009.04.016","article-title":"Prepulse inhibition deficits in schizophrenia are modified by smoking status","volume":"112","author":"Woznica","year":"2009","journal-title":"Schizophr Res"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584613001516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584613001516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T22:04:29Z","timestamp":1563487469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584613001516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":92,"alternative-id":["S0278584613001516"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2013.07.010","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurocognitive endophenotypes in schizophrenia: Modulation by nicotinic receptor systems","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2013.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}